Eotaxin, an Endogenous Cognitive Deteriorating Chemokine (ECDC), Is a Major Contributor to Cognitive Decline in Normal People and to Executive, Memory, and Sustained Attention Deficits, Formal Thought Disorders, and Psychopathology in Schizophrenia Patients.
Cytokines
Immune
Inflammation
Interleukin
Neurocognition
Schizophrenia
Journal
Neurotoxicity research
ISSN: 1476-3524
Titre abrégé: Neurotox Res
Pays: United States
ID NLM: 100929017
Informations de publication
Date de publication:
Jan 2019
Jan 2019
Historique:
received:
18
06
2018
accepted:
18
07
2018
revised:
12
07
2018
pubmed:
30
7
2018
medline:
21
3
2019
entrez:
30
7
2018
Statut:
ppublish
Résumé
Eotaxin is increased in neurodegenerative disorders and schizophrenia, and preclinical studies indicate that eotaxin may induce cognitive deficits. This study aims to examine whether peripheral levels of eotaxin impact cognitive functioning in healthy volunteers and formal thought disorder (FTD) and psychopathology in schizophrenia patients. Serum levels of eotaxin were assayed and cognitive tests were performed on a sample of 40 healthy participants and 80 schizophrenia patients. Among healthy participants, eotaxin levels were significantly associated with episodic/semantic memory, executive functions, Mini Mental State Examination, emotion recognition, and sustained attention. In addition, age-related effects on these cognitive measures were partly mediated by eotaxin. The super-variable "age-eotaxin" predicted a large part of the variance in cognitive functions among healthy participants, and hence, eotaxin may act as an "accelerated brain aging chemokine" (ABAC). In schizophrenia, eotaxin levels had a strong impact on formal thought disorders and psychopathology. In schizophrenia, increased eotaxin strongly impacts memory and sustained attention, which together to a large extent determine FTD. FTD together with memory deficits predicts around 92.5% of the variance in psychopathology. Moreover, the effects of eotaxin are partially mediated by executive functioning, while the effects of male sex on FTD and psychopathology are mediated by eotaxin. In healthy subjects, eotaxin strongly impacts executive functioning and multiple cognitive domains. In schizophrenia, peripheral levels of eotaxin strongly impact both negative symptoms and psychosis (hallucinations and delusions), and these eotaxin effects are mediated by impairments in frontal functioning, memory, sustained attention, and FTD. Eotaxin is an endogenous cognitive deteriorating chemokine (ECDC) and a novel therapeutic target for age-related cognitive decline and schizophrenia as well.
Identifiants
pubmed: 30056534
doi: 10.1007/s12640-018-9937-8
pii: 10.1007/s12640-018-9937-8
doi:
Substances chimiques
Biomarkers
0
CCL11 protein, human
0
Chemokine CCL11
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
122-138Subventions
Organisme : Asahi Glass Foundation
ID : NA
Organisme : Ratchadapiseksompotch Fund,
ID : RA60/042
Références
Brain Res Brain Res Rev. 2000 Mar;31(2-3):357-63
pubmed: 10719163
J Allergy Clin Immunol. 2001 Oct;108(4):594-601
pubmed: 11590387
J Psychosom Res. 2002 Jun;52(6):501-9
pubmed: 12069875
Psychoneuroendocrinology. 2003 Apr;28 Suppl 2:17-54
pubmed: 12650680
J Abnorm Psychol. 2003 Aug;112(3):339-52
pubmed: 12943013
Br J Med Psychol. 1959;32(1):50-5
pubmed: 13638508
J Cogn Neurosci. 2005 Jul;17(7):994-1010
pubmed: 16102232
Schizophr Bull. 2006 Apr;32(2):250-8
pubmed: 16221995
J Investig Allergol Clin Immunol. 2005;15(4):277-82
pubmed: 16433209
Schizophr Res. 2006 Jul;85(1-3):84-95
pubmed: 16624529
J Mol Endocrinol. 2007 Mar;38(3):351-3
pubmed: 17339397
Brain. 2007 Sep;130(Pt 9):2387-400
pubmed: 17690132
Prog Neuropsychopharmacol Biol Psychiatry. 2008 Apr 1;32(3):710-4
pubmed: 18096286
J Neuroimmunol. 2009 Nov 30;216(1-2):66-75
pubmed: 19818514
Eur J Immunol. 2010 Feb;40(2):406-16
pubmed: 19950176
Br J Psychiatry. 1991 Mar;158:307-16
pubmed: 2036527
Nature. 2011 Aug 31;477(7362):90-4
pubmed: 21886162
Arch Gen Psychiatry. 2011 Sep;68(9):961-9
pubmed: 21893661
Arch Gen Psychiatry. 2012 Jun;69(6):562-71
pubmed: 22664547
PLoS One. 2012;7(7):e39794
pubmed: 22815714
Proc Natl Acad Sci U S A. 2013 Feb 5;110(6):2264-9
pubmed: 23335631
Front Psychiatry. 2013 Jun 24;4:35
pubmed: 23805107
Schizophr Res. 2014 Feb;152(2-3):528-9
pubmed: 24439271
J Pharmacol Exp Ther. 2014 Jun;349(3):497-507
pubmed: 24706984
Clin Immunol. 2014 Jul;153(1):199-208
pubmed: 24786916
Rejuvenation Res. 2014 Dec;17(6):525-8
pubmed: 25400086
Int J Neuropsychopharmacol. 2014 Oct 31;18(4):null
pubmed: 25522386
Schizophr Res. 2015 May;164(1-3):53-8
pubmed: 25716958
Psychiatry Res. 1989 Nov;30(2):119-23
pubmed: 2616682
World J Biol Psychiatry. 2015 Sep;16(6):422-429
pubmed: 26212792
Mol Psychiatry. 2015 Nov;20(11):1294-300
pubmed: 26324103
Mol Neurobiol. 2016 Oct;53(8):5701-9
pubmed: 26491028
Br J Psychiatry Suppl. 1989 Nov;(7):49-58
pubmed: 2695141
Braz J Psychiatry. 2016 Apr 19;38(2):121-6
pubmed: 27096410
Alzheimers Dement (Amst). 2016 Jun 22;3:91-7
pubmed: 27453930
Compr Psychiatry. 2016 Oct;70:209-15
pubmed: 27565775
Oncotarget. 2016 Oct 4;7(40):64711-64725
pubmed: 27589839
Schizophr Res. 2016 Dec;178(1-3):29-34
pubmed: 27639419
Int J Geriatr Psychiatry. 2017 Dec;32(12):1226-1232
pubmed: 27645461
Mol Neurobiol. 2017 Dec;54(10):7964-7978
pubmed: 27878757
Transl Stroke Res. 2017 Dec;8(6):578-584
pubmed: 28634890
Prog Neuropsychopharmacol Biol Psychiatry. 2018 Jan 3;80(Pt C):168-176
pubmed: 28666826
Mol Neurobiol. 2018 Jun;55(6):5184-5201
pubmed: 28875464
PLoS One. 2017 Sep 26;12(9):e0185541
pubmed: 28950005
Front Aging Neurosci. 2017 Dec 01;9:402
pubmed: 29249965
Metab Brain Dis. 2018 Aug;33(4):1053-1067
pubmed: 29527624
Lancet Psychiatry. 2018 Jun;5(6):515-526
pubmed: 29678679
Brain Behav Immun. 2018 Jul;71:28-36
pubmed: 29730395
J Eval Clin Pract. 2018 Aug;24(4):879-891
pubmed: 29790237
Psychol Med. 1987 Feb;17(1):49-57
pubmed: 3575577
Schizophr Bull. 1987;13(2):261-76
pubmed: 3616518
Schizophr Bull. 1986;12(3):348-59
pubmed: 3764356
Psychiatry Res. 1985 Aug;15(4):313-8
pubmed: 3865247
Br J Psychiatry. 1972 Jan;120(554):3-17
pubmed: 4557434
Arch Gen Psychiatry. 1982 Jul;39(7):789-94
pubmed: 7165478
Eur Arch Psychiatry Clin Neurosci. 1995;244(6):325-9
pubmed: 7772617
Acta Psychiatr Scand. 1994 May;89(5):346-51
pubmed: 8067274
Eur J Immunol. 1997 Dec;27(12):3507-16
pubmed: 9464841
J Immunol. 1998 Jan 1;160(1):60-8
pubmed: 9551956